Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1

Sunbin Ling, Hai-yang Xie, +8 authors Shu-sen Zheng
Published 2017 in Journal of hematology & oncology

Abstract

BACKGROUND Arsenic trioxide (ATO) is commonly used in the treatment of acute promyelocytic leukemia (APL), but does not benefit patients with solid tumors. When combined with other agents or radiation, ATO showed treatment benefits with manageable toxicity. Previously, we reported that metformin amplified the inhibitory effect of ATO on intrahepatic… (More)

DOI: 10.1186/s13045-017-0424-0

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Cited By

Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells

Jiancheng Wang, Xin Liu, +13 authors Andy Peng Xiang
Journal of hematology & oncology
2018

Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Tao Wang, Chunyan Cheng, +6 authors Jianqing Mi
Journal of cellular and molecular medicine
2018

Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma

Weijian Sun, Bin He, +10 authors Shusen Zheng
Laboratory Investigation
2018

References

Sort by:

Showing 1-10 of 38 references

The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase.

F V Lali, A E Hunt, S J Turner, B M Foxwell
The Journal of biological chemistry
2000

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Ting-Chao Chou
Pharmacological reviews
2006

Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Y Shimizu, A J Demetris, +6 authors T L Whiteside
International journal of cancer
1992

Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy depletion-induced suppression of mTORC1

Min Zheng, Yan-Hai Wang, +8 authors Jiahuai Han
Nature Cell Biology
2011

Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: ménage à trois or ménage à quatre?

Alexey Shiryaev, Ugo Moens
Cellular signalling
2010

Steelman LS Chappell WH Abrams SL Montalto G Cervello M et al. Mutations McCubrey JA, deregulation of RasRafMEKERK, PI3KPTEN AktmTOR cascades which alter therapy response. Oncotarget. 2012, 39
Ling et al. Journal of Hematology & Oncology
2017

Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer.

Ke-Jie Chang, Meng-Hang Yang, Jin-Cheng Zheng, Bing Li, Wei Nie
American journal of translational research
2016

Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.

Mingxiao Lang, Xiuchao Wang, +9 authors He Ren
Cancer letters
2016

Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells

Sun-Mi Yun, Sang Hyeok Woo, +11 authors In-Chul Park
Molecular and Cellular Endocrinology
2016

Metformin does not improve survival of cholangiocarcinoma patients with diabetes.

Zhen Yang, Xiaodan Zhang, Rosebud O Roberts, Lewis R Roberts, Roongruedee Chaiteerakij
Hepatology
2016

Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1

Abstract

Topics

Figures and Tables

Cited By

Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells

Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma

References

The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase.

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy depletion-induced suppression of mTORC1

Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: ménage à trois or ménage à quatre?

954–87

Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer.

Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.

Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells

Metformin does not improve survival of cholangiocarcinoma patients with diabetes.

Slides referencing similar topics

Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1

Abstract

Topics

Figures and Tables

Cited By

Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells

Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma

References

The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase.

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy depletion-induced suppression of mTORC1

Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: ménage à trois or ménage à quatre?

954–87

Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer.

Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.

Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells

Metformin does not improve survival of cholangiocarcinoma patients with diabetes.

Similar Papers

Slides referencing similar topics